Krishnan R, Jadhav M, John T J
Bull World Health Organ. 1983;61(4):689-92.
The immunogenic efficacy of inactivated (Salk) poliovirus vaccine (IPV) was evaluated in infants in India, in view of the high frequency of vaccine failure after immunization with oral (Sabin) poliovirus vaccine (OPV). A total of 150 infants, aged 6-45 weeks, were given 3 doses of IPV, with intervals of 4 or 8 weeks between doses. The effect on the antibody response of child's age, presence of maternal antibody before immunization, and interval between doses was assessed. The overall seroconversion rates to poliovirus types 1, 2, and 3 were 99%, 89%, and 91%, respectively. Seroconversion rates to types 2 and 3, and antibody titres to types 1 and 2, were higher (i) in infants given vaccine doses at 8-week intervals and (ii) in those without detectable maternal antibody. The seroconversion rates in infants without maternal antibody, who were given IPV at 8-week intervals, were 100%, 100%, and 96.2% to poliovirus types 1, 2, and 3, respectively. Thus the immunogenic efficacy of IPV was found to be satisfactory.
鉴于口服（萨宾）脊髓灰质炎疫苗（OPV）免疫后疫苗失败的频率较高，在印度对婴儿评估了灭活（索尔克）脊髓灰质炎疫苗（IPV）的免疫原性疗效。共有150名6至45周龄的婴儿接种了3剂IPV，各剂之间间隔4周或8周。评估了儿童年龄、免疫前母体抗体的存在以及各剂之间的间隔对抗体反应的影响。对脊髓灰质炎病毒1型、2型和3型的总体血清转化率分别为99%、89%和91%。（i）每隔8周接种一剂疫苗的婴儿以及（ii）未检测到母体抗体的婴儿中，对2型和3型的血清转化率以及对1型和2型的抗体滴度更高。每隔8周接种IPV的无母体抗体婴儿中，对脊髓灰质炎病毒1型、2型和3型的血清转化率分别为100%、100%和96.2%。因此，发现IPV的免疫原性疗效令人满意。
